Piramal Pharma’s solutions business has announced the expansion of its Antibody-Drug Conjugate (ADC) capabilities at the Grangemouth facility.
Along with investment in new infrastructure at its Morpeth facility, these expansions and upgrades represent a total investment of approximately £55m in the Indian company’s UK-based drug development and manufacturing capabilities, as well as new employment opportunities for technical and operational staff.
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by the third quarter of 2023, will be added to the existing three.
